Physician profile
Nitasha Khullar
NPI 1134581663
$2,513.38
in general payments reported to CMS, 2019-2025
11 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $332 · 2024: $1,743 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $545.52 | 2023-2024 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $462.65 | 2024-2025 | |
| Janssen Biotech, INC. | $322.37 | 2023-2025 | Tremfya |
| Glaxosmithkline, LLC. | $309.09 | 2023-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $263.79 | 2023-2025 | |
| Ucb, INC. | $190.12 | 2024-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $181.05 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $161.96 | 2024-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.51 | 2024 | Ofev |
| Lilly USA, LLC | $28.50 | 2025 | Taltz |
| Sandoz INC. | $19.82 | 2024 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitasha Khullar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.